Enlicitide for Healthy Subjects

This trial aims to understand how a new treatment called enlicitide behaves in a healthy person's body over time and to assess its safety. Participants will receive one of three different oral doses of enlicitide. The study seeks healthy individuals with a body-mass index (BMI) between 18 and 32, without a history of significant gastrointestinal issues or cancer. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators.

Research has shown that enlicitide is generally safe and well-tolerated. Studies have found its safety profile to be similar to that of a placebo, a harmless pill used for comparison. In previous studies, serious side effects occurred in 10% of participants taking enlicitide, compared to 12% in those taking a placebo. This suggests that enlicitide does not cause more serious side effects than a non-active treatment. Additionally, the number of unwanted side effects was similar between the enlicitide and placebo groups. Overall, based on available data, enlicitide appears safe for use.¹²³⁴⁵

Enlicitide is unique because it introduces a novel approach to treatment by being administered orally, which is a convenient alternative compared to many standard treatments that often require injections or infusions. Researchers are particularly excited about its potential new mechanism of action, which could offer different benefits or target pathways not addressed by existing therapies. This could mean better outcomes or fewer side effects for patients, setting enlicitide apart from traditional options.

Research has shown that enlicitide effectively lowers LDL-C, often referred to as "bad cholesterol." Studies have found that enlicitide significantly reduces LDL-C levels. In one study, 70.3% of patients lowered their LDL-C to below 70 mg/dL, and more than half experienced a decrease from their starting levels. Most patients tolerated the treatment well, with safety comparable to those taking a placebo. These findings suggest that enlicitide could be a promising option for managing cholesterol-related conditions. Participants in this trial will receive enlicitide in different dose regimens to further evaluate its effects and safety.¹⁶⁷⁸⁹